Quick Summary — NIM scores higher on quality with 1.8/10 vs NHS's 1.7/10. NHS trades at $6.39 while NIM trades at $9.26. Both analyzed daily using SEC EDGAR data across 13 institutional models.
NIM scores higher with a 1.8/10 quality rating vs NHS's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $6.39, NHS trades +74.0% above its Bayesian DCF fair value of $1.66, while NIM at $9.26 trades +74.0% above its estimate of $2.41. NHS shows a wider gap between price and intrinsic value.
NHS earns a Quality of Company score of 1.7/10 compared to NIM's 1.8/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both NHS and NIM to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both NHS and NIM operate in Asset Management, which has 448 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare NHS vs NIM differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.